Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome - Wikidata - wikimedia - TriplyDB

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

http://www.wikidata.org/entity/Q34034427

about

Vitamin D in hematological disorders and malignancies.Clinical experience using vitamin d and analogs in the treatment of myelodysplasia and acute myeloid leukemia: a review of the literature.The role of vitamin D in hematologic disease and stem cell transplantation.Is there a role for differentiating therapy in non-APL AML?Phosphorylation of Human Retinoid X Receptor α at Serine 260 Impairs Its Subcellular Localization, Receptor Interaction, Nuclear Mobility, and 1α,25-Dihydroxyvitamin D3-dependent DNA Binding in Ras-transformed Keratinocytes.Vitamin D Control of Hematopoietic Cell Differentiation and Leukemia.Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.

P2860

Q30275725-ADB883A1-CE62-483B-A992-714AED0C9812 Q36417543-529F97CD-3137-4351-9F6C-6647F70C5D6A Q37050872-9EEEEF20-F9BE-4267-911C-D7F76C115270 Q37815790-9A2F4954-7076-495F-9678-F8FB17408EEE Q38730810-082C9775-27BC-4E78-9A2C-233AE7CF99A4 Q39037456-E6AC10BD-12C3-4E9C-97D2-164120245E59 Q42598206-8A58FA5D-B862-4258-9CDA-21995D94E045

P2860

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

http://www.wikidata.org/entity/Q34034427

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

@ast

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

@en

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

@nl

type

label

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

@ast

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

@en

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

@nl

prefLabel

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

@ast

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

@en

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

@nl

P1433

Q34034427-F2AE10C7-2786-4D82-A130-BC5C5C9DFD3B

P1476

Q34034427-BA84CA59-F797-4873-8884-E030907482D5

P2093

Q34034427-20886564-4A13-40AD-AD91-FD82E9FDED77

Q34034427-447E849C-6778-4DB0-BE3B-6052A442FCEF

Q34034427-8CE3FDF4-8C87-4486-A3A5-6843855AE773

Q34034427-8E1BF74C-8C12-45AF-9760-C358D2EDC539

Q34034427-91A08A75-22A8-4D5E-9CC4-80C66EF8525B

Q34034427-AC0B304C-E71C-4669-907B-590F4069EC22

P2860

Q34034427-1179A90A-FC6E-4797-8D31-3AB56DFD9730

Q34034427-164E03F8-DC3B-4840-BB5D-3491D9218EAF

Q34034427-2CC56683-25D8-469B-8297-1B28DD53512D

Q34034427-362A4946-52AD-4D0A-95EF-E9D417FA5BBD

Q34034427-4B474113-3253-40D4-A45B-265C889C2E7B

Q34034427-5D30D65A-DFC7-4CB7-9E84-8AFC326DC740

Q34034427-81E4D0C5-B1F5-419F-A095-BD78211A3038

Q34034427-915FFB65-96B4-4E87-A450-692564530F11

Q34034427-9C18500D-72F7-427E-91BB-73BEDF91A7FD

Q34034427-A9FD7C00-E2D5-44A7-9085-41C1D15A528B

P304

Q34034427-F7CB3BF1-0F9C-4FBF-A7E5-2CA0506D655D

P31

Q34034427-C9EC824B-8855-411A-BF77-7AA75B6C7B2F

P356

Q34034427-C5FE58B4-DFDD-468C-AAAB-8421DDC4BA3D

P433

Q34034427-46C34F55-8DB9-45C5-B1C4-54F113093F52

P478

Q34034427-91FEA60F-0670-49D5-8D8E-E8E864868106

P577

Q34034427-8D74CD34-B405-4B26-8D4C-BAB847C7AC55

P5875

Q34034427-3EE30600-A54B-4538-8560-6257B618823F

P698

Q34034427-EB9DA1E6-5406-4979-8054-2505045BB9D9

P932

Q34034427-EB6D71BE-1973-41D1-A6C7-EFCC6EDE917D

P356

10428190701713648

P1433

Leukemia & Lymphoma

P1476

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

@en

P2093

Adam Petrich

http://www.w3.org/2001/XMLSchema#string

Brad Kahl

http://www.w3.org/2001/XMLSchema#string

Howard Bailey

http://www.w3.org/2001/XMLSchema#string

Kyungmann Kim

http://www.w3.org/2001/XMLSchema#string

Mark Juckett

http://www.w3.org/2001/XMLSchema#string

Nancy Turman

http://www.w3.org/2001/XMLSchema#string

P2860

International scoring system for evaluating prognosis in myelodysplastic syndromes

Myelodysplasia.

Drug development in prostate cancer.

Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.

19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

1,25(OH)2D3-modulated calcium induced keratinocyte differentiation.

Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer.

Optimal two-stage designs for phase II clinical trials.

Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome.

P304

57-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190701713648

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5648571

http://www.w3.org/2001/XMLSchema#string

P698

18203012

http://www.w3.org/2001/XMLSchema#string

P932

2913589

http://www.w3.org/2001/XMLSchema#string